Neurology

MRI of the brain
#epilepsy #Longboard Pharmaceuticals #Lundbeck #Mergers and acquisitions #Neurology

Acquisition to strengthen neuroscience pipeline

Lundbeck and Longboard Pharmaceuticals have announced an agreement for Lundbeck to acquire Longboard. Longboard is a clinical-stage biopharmaceutical company focused on developing novel medicines for neurological diseases. Its lead asset, bexicaserin, has shown encouraging anti-seizure reduction to date in preclinical and clinical studies, with its next-generation superagonist mechanism specifically targeting… Read More

#Business & Investment #News

#Antidepressants #Neurology #Neuropsychiatric disorders #Neuroscience #Psychedelics #Psychiatry

Reshaping neuropsychiatry

Dr Anantha Shekhar, MD PhD, Dean of the University of Pittsburgh School of Medicine, explores synapse structure and function in neuroscience and how neuroplasticity can present new opportunities for drug development. With contributions from Rob Houghtaling, MS and John Donello, PhD, Gate Neurosciences. In March 2019, the US FDA approved… Read More

#Exclusive Content

Toxoplasma gondii
#Neurodegenerative disorders #Neurology #Parasitic disease #Tel Aviv University #University of Glasgow

Engineered brain parasites could treat cognitive disorders

Researchers have discovered a way of using engineered brain parasites to deliver treatments for neurological conditions across the blood-brain-barrier. The study – led by the University of Glasgow in collaboration with Tel Aviv University and an international team of researchers – represents an exciting new field… Read More

#Editor's Choice #News

#Brain disease #Johnson & Johnson #Neurology #Neuroscience

Shaping the future of neuroscience

Berkin Gökbudak, Senior Director of Commercial Strategy for Neuroscience, Pulmonary Hypertension & Cardiovascular & Metabolism, at Johnson & Johnson, looks towards neuroscience strategies that can help advance treatments for brain disorders. The human brain is the last, and greatest, scientific frontier – it’s been described as the most complex structure… Read More

#Exclusive Content

#Amyotrophic lateral sclerosis (ALS) #Dementia #epilepsy #Neurodegenerative disorders #Neurology #Neuroscience #Parkinson's

New DDW Highlights podcast: 29 July 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. There have been some interesting developments in neuroscience this week. Perhaps most note-worthy,… Read More

#News

#Amyotrophic lateral sclerosis (ALS) #Dementia #epilepsy #Neurodegenerative disorders #Neurology #Neuroscience #Parkinson's

This week in drug discovery (22-26 July) 

News round-up for 22-26 July by DDW Senior Digital Content Editor Diana Spencer. There have been some interesting developments in neuroscience this week. Perhaps most note-worthy, shingles vaccines Shingrix has been shown to reduce the risk of dementia by 17%, and TikoMed’s ALS drug caused a long-term slowing… Read More

#News

Cancer research
#Amyotrophic lateral sclerosis (ALS) #Neurology #Neuroscience #Phase II trial #TikoMed

‘Encouraging’ results for potential disease-modifying ALS drug

New clinical data have shown that TikoMed’s low molecular weight dextran sulfate compound ILB is safe and well tolerated in patients with amyotrophic lateral sclerosis (ALS). The trial was carried out at the Queen Elizabeth Hospital, Birmingham, UK, by the University of Birmingham’s Drugs, Devices, Diagnostics… Read More

#Editor's Choice #News

Autoantibodies bond to receptor (achr) blocking the acetylcholine transmitters in Myasthenia gravis (MG).
#Antibody Fragments #argenx #Autoimmune disease #Events #Neurology

Antibody fragment shows promise in myasthenia gravis

argenx shared trial and real-world data on Vyvgart (efgartigimod alfa) in patients with generalised myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive at the European Academy of Neurology (EAN) Annual Meeting. In gMG, Vyvgart demonstrated consistent and repeatable improvements across patient subtypes, a… Read More

#News

#Clinical trials #Neurodegenerative disorders #Neurology #Neuroscience

DDW Highlights podcast expands to include vodcast 

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   This week has seen… Read More

#News

Monoclonal antibody
#Autoimmune disease #Janssen #Monoclonal antibodies #Neurology #Phase III trial

Janssen reports positive data for myasthenia gravis treatment

Janssen-Cilag has reported positive results from its Phase III Vivacity-MG3 study assessing its nipocalimab therapy for the treatment of patients with generalised myasthenia gravis (gMG). The Johnson & Johnson company showcased the data in a presentation at the European Academy of Neurology (EAN) 2024 Congress and… Read More

#News

#Clinical trials #Neurodegenerative disorders #Neurology #Neuroscience

New DDW Highlights podcast: 1 July 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. It is also available to watch as a vodcast:  This week… Read More

#News

#Clinical trials #Neurodegenerative disorders #Neurology #Neuroscience

This week in drug discovery (24-28 June) 

News round-up for 24-28 June by DDW Senior Digital Content Editor Diana Spencer. This week has seen some exciting advances in neuroscience drug discovery, including Phase II clinical trials for two potentially game-changing treatments, a synapse-regenerating drug for Alzheimer’s and a gene therapy for Parkinson’s, as well as… Read More

#News

#Assays #Case study #Drug development #Drug discovery #iPSC #Neurology

Case Study: Consistent assays for neurological drug development

A new Case Study is now available to download for free entitled ‘Improving physiological relevance in neurological disease drug development.’ In this case study, hear from Elise Malavasi, PhD, a Principal Scientist at leading contract research organisation Concept Life Sciences. The interview highlights their need to develop… Read More

#News

Case Study: Improving physiological relevance in neurological disease drug development
#Assays #Drug development #Drug discovery #iPSC #Neurology

Improving physiological relevance in neurological disease drug development

In this case study, hear from Elise Malavasi, PhD, a Principal Scientist at leading contract research organisation Concept Life Sciences. The interview highlights their need to develop assays that are amenable to long term use to support their clients with drug development, and how bit.bio’s deterministically programmed ioMicroglia have helped… Read More

#Resources

#EG 427 #Gene therapy #Neurology #Phase II trial

First gene therapy for bladder condition enters clinical study

Biotechnology company EG 427 has revealed plans to start a Phase Ib/IIa clinical study in neurogenic detrusor overactivity (NDO), following Investigational New Drug (IND) clearance from the US Food and Drug Administration (FDA). NDO is a severe bladder condition affecting patients living with spinal cord injury,… Read More

#News

CAR-T therapy
#Autoimmune disease #CAR-T #Cell therapy #Kyverna Therapeutics #Neurology

First use of CAR-T therapy in patient with stiff-person syndrome

KYV-101, a fully human anti-CD19 chimeric antigen receptor (CAR) T-cell product candidate, has been used to treat a 69-year-old patient suffering from treatment-refractory stiff-person syndrome (SPS). The therapy was given as part of a named-patient use in Germany for critically ill individuals who fail conventional therapies. Read More

#News